Kenny Walter

"The best test is the 1 that gets done," Williams said.

In a late-breaking abstract, the investigators compared antibody levels at month 6 compared to month 1.

A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index

The agency has set an April 26, 2023 action date for the live microbiotic therapeutic for the prevention of recurrent CDI.

Dupilumab represents the first ever approved treatment for EoE.

The median DeMeester score decreased from 32-3.7 following LTF.

If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.

The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.

The approval of risankizumab represents the first IL-23 approved for IBD.

Falloon presented new data at ACG 2022 on identifying biomarkers for pouch inflammation.

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.

The rate of serious infections was 5.9 events per 100 person-years in the placebo group, compared to 5.0 events in the upadacitinib 15 mg cohort and 3.2 upadacitinib 30 mg group.

In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Bezlotoxumab is a fully humanized monoclonal antibody approved by the US Food and Drug Administration in 2017 for the prevention of recurrent CDI.

Dermatologists and primary care physicians believe there is a significant unmet need for treatments for patients with mild or moderate atopic dermatitis.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.

PASI 100 was achieved by 28% of patients in week 4, 89% in week 12, and 68% in week 36.

At 14 week, 33% of patients in the 210 mg induction etrolizumab group were in clinical remission, compared to 29% of the placebo induction group.

Approximately 5% of nurses in Mozambique were infected with hepatitis B virus during a 3-month period in 2020.

Several factors that impaired healing included former smoking and seton insertion.

The Recap of Atopic Eczema (RECAP) and Atopic Dermatitis Control Tool (ADCT) were recommended to measure eczema control.

Women who were socially isolated were more likely to have insomnia than women who were socially integrated.

Overall, secukinumab was more effective in biologic-naïve patients and in patients with a lower body mass index (BMI).

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.

The estimated annual percentage change was signficiantly associated with a baseline age-standardized incidence rate of less than 5500 per 100,000 individuals.

The slight benefit could be attributed to a lower than expected adherence to screening requests.

An increase of 1 microgram/m3 in PM2.5 or 1% in toxic releases equates to an increase in the IBS incidence rate of about 0.02 cases per 100 person-years.

There is no evidence in the value of screening for depression in individuals aged 11 years and younger.

In total, 64.9% of patients who achieved clinical response with ustekinumab during induction were in symptomatic remission after 44 weeks.